These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 11086633)

  • 21. Angiotensin II type 1 receptor blockers.
    Burnier M
    Circulation; 2001 Feb; 103(6):904-12. PubMed ID: 11171802
    [No Abstract]   [Full Text] [Related]  

  • 22. [Antihypertensive advantages of angiotensin II AT1 receptor antagonism].
    Coca A; Giner V
    Rev Esp Cardiol; 1999; 52 Suppl 3():53-8. PubMed ID: 10614150
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improving prognosis in hypertension: exploring the benefits of angiotensin II type 1 receptor blockade.
    Ruilope L
    Blood Press Suppl; 2000; 1():31-5. PubMed ID: 11059634
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Candesartan cilexetil: an angiotensin II-receptor blocker.
    See S; Stirling AL
    Am J Health Syst Pharm; 2000 Apr; 57(8):739-46. PubMed ID: 10786259
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of candesartan cilexetil and enalapril on structural alterations and endothelial function in small resistance arteries of spontaneously hypertensive rats.
    Rizzoni D; Porteri E; Bettoni G; Piccoli A; Castellano M; Muiesan ML; Pasini G; Guelfi D; Rosei EA
    J Cardiovasc Pharmacol; 1998 Nov; 32(5):798-806. PubMed ID: 9821855
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Candesartan cilexetil: an angiotensin II receptor blocker.
    Stoukides CA; McVoy HJ; Kaul AF
    Ann Pharmacother; 1999 Dec; 33(12):1287-98. PubMed ID: 10630830
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Angiotensin II receptor antagonist TCV-116 induces regression of hypertensive left ventricular hypertrophy in vivo and inhibits the intracellular signaling pathway of stretch-mediated cardiomyocyte hypertrophy in vitro.
    Kojima M; Shiojima I; Yamazaki T; Komuro I; Zou Z; Wang Y; Mizuno T; Ueki K; Tobe K; Kadowaki T
    Circulation; 1994 May; 89(5):2204-11. PubMed ID: 8181146
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differences among angiotensin II type 1 receptor blockers: characteristics of candesartan cilexetil.
    Unger T
    Blood Press Suppl; 2000; 1():14-8. PubMed ID: 11059630
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Angiotensin II receptor blockers: equal or preferred substitutes for ACE inhibitors?
    Grossman E; Messerli FH; Neutel JM
    Arch Intern Med; 2000 Jul; 160(13):1905-11. PubMed ID: 10888965
    [No Abstract]   [Full Text] [Related]  

  • 30. Long-acting blood pressure reduction by candesartan cilexetil in patients with hypertension.
    Bönner G; Fuchs W
    Curr Med Res Opin; 2005 Jun; 21(6):935-40. PubMed ID: 15969893
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Angiotensin receptor antagonist for therapy of patients with hypertension].
    Rakugi H; Ogihara T
    Nihon Rinsho; 1997 Aug; 55(8):2075-80. PubMed ID: 9284426
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transcriptomic Response in the Heart and Kidney to Different Types of Antihypertensive Drug Administration.
    Takeuchi F; Liang YQ; Isono M; Ang MY; Mori K; Kato N
    Hypertension; 2022 Feb; 79(2):413-423. PubMed ID: 34879704
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of acute AT1 receptor blockade by candesartan on arterial pressure and renal function in rats.
    Cervenka L; Wang CT; Navar LG
    Am J Physiol; 1998 May; 274(5):F940-5. PubMed ID: 9612332
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Angiotensin II type 1 (AT1) receptor blockade in hypertensive women: benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide.
    Malmqvist K; Kahan T; Dahl M
    Am J Hypertens; 2000 May; 13(5 Pt 1):504-11. PubMed ID: 10826401
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Significance of angiotensin type 1 receptor blockade: why are angiotensin II receptor blockers different?
    Unger T
    Am J Cardiol; 1999 Nov; 84(10A):9S-15S. PubMed ID: 10588089
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Angiotensin-II receptor antagonists: their place in therapy.
    Kirk JK
    Am Fam Physician; 1999 Jun; 59(11):3140-8. PubMed ID: 10392595
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Direct inhibition of renin as a cardiovascular pharmacotherapy: focus on aliskiren.
    Sepehrdad R; Frishman WH; Stier CT; Sica DA
    Cardiol Rev; 2007; 15(5):242-56. PubMed ID: 17700383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypotensive activity of TCV-116, a newly developed angiotensin II receptor antagonist, in spontaneously hypertensive rats.
    Mizuno K; Niimura S; Tani M; Saito I; Sanada H; Takahashi M; Okazaki K; Yamaguchi M; Fukuchi S
    Life Sci; 1992; 51(20):PL183-7. PubMed ID: 1435062
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiovascular effects of inhibition of renin-angiotensin-aldosterone system components in hypertensive rats given salt excess.
    Susic D; Varagic J; Frohlich ED
    Am J Physiol Heart Circ Physiol; 2010 Apr; 298(4):H1177-81. PubMed ID: 20118410
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison between the angiotensin II receptor antagonist candesartan cilexetil and the angiotensin-converting enzyme inhibitor trandolapril in microalbuminuria of patients with early diabetic nephropathy.
    Nakamura T; Ushiyama C; Suzuki S; Shimada N; Sekizuka K; Ebihara I; Takahashi Y; Tanaka A; Koide H
    Nephron; 2000 Oct; 86(2):247. PubMed ID: 11015024
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.